These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 4002188)

  • 61. [Control of the quality of drug doses in the framework of therapeutic surveillance: Asqualab program 1997-1999].
    Feuillu A; Anglard I; Morel I; Palette C; Marquet P; Roux A; Vassault A
    Ann Biol Clin (Paris); 2000; 58(5):630-6. PubMed ID: 11022111
    [No Abstract]   [Full Text] [Related]  

  • 62. The drug safety review process.
    Somberg J
    Am J Ther; 2007; 14(2):119. PubMed ID: 17414577
    [No Abstract]   [Full Text] [Related]  

  • 63. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL; Kung MF
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A new method for assessing drug causation provided agreement with experts' judgment.
    Arimone Y; Bégaud B; Miremont-Salamé G; Fourrier-Réglat A; Molimard M; Moore N; Haramburu F
    J Clin Epidemiol; 2006 Mar; 59(3):308-14. PubMed ID: 16488362
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [More transparency in drug safety].
    Saussele T
    Med Monatsschr Pharm; 2009 Sep; 32(9):325. PubMed ID: 19795694
    [No Abstract]   [Full Text] [Related]  

  • 66. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Unwanted drug interactions. Keeping up pharmacovigilance using databases].
    Schindler B
    Med Monatsschr Pharm; 2008 Apr; 31(4):155-6. PubMed ID: 18497254
    [No Abstract]   [Full Text] [Related]  

  • 68. Current status of the drug safety monitoring system in Korea.
    Park BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840
    [No Abstract]   [Full Text] [Related]  

  • 69. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Switzerland's drug surveillance.
    Sahli HR
    Lancet; 1989 Sep; 2(8664):678. PubMed ID: 2570927
    [No Abstract]   [Full Text] [Related]  

  • 73. Drugs best avoided yet still on the market in early 2012.
    Prescrire Int; 2012 Apr; 21(126):108. PubMed ID: 22515142
    [No Abstract]   [Full Text] [Related]  

  • 74. [Imputability is not a synonym for responsibility].
    Lagier G; Dally S; Fournier E
    Therapie; 1986; 41(3):215-7. PubMed ID: 3750261
    [No Abstract]   [Full Text] [Related]  

  • 75. Do unpredictable toxic side-effects of drugs reflect their promiscuous binding energies?
    Wiseman A
    Trends Pharmacol Sci; 2003 Feb; 24(2):61-2. PubMed ID: 12559766
    [No Abstract]   [Full Text] [Related]  

  • 76. A method for estimating the probability of adverse drug reactions.
    Naranjo CA; Busto U; Sellers EM; Sandor P; Ruiz I; Roberts EA; Janecek E; Domecq C; Greenblatt DJ
    Clin Pharmacol Ther; 1981 Aug; 30(2):239-45. PubMed ID: 7249508
    [No Abstract]   [Full Text] [Related]  

  • 77. Toward the operational identification of adverse drug reactions.
    Karch FE; Lasagna L
    Clin Pharmacol Ther; 1977 Mar; 21(3):247-54. PubMed ID: 837643
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Mehtod for determination of undesirable effects of drugs].
    Dangoumau J; Evreux JC; Jouglard J
    Therapie; 1978; 33(3):373-81. PubMed ID: 684688
    [No Abstract]   [Full Text] [Related]  

  • 79. The use of skin testing in the investigation of cutaneous adverse drug reactions.
    Barbaud A; Reichert-Penetrat S; Tréchot P; Jacquin-Petit MA; Ehlinger A; Noirez V; Faure GC; Schmutz JL; Béné MC
    Br J Dermatol; 1998 Jul; 139(1):49-58. PubMed ID: 9764148
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.
    Danan G; Benichou C
    J Clin Epidemiol; 1993 Nov; 46(11):1323-30. PubMed ID: 8229110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.